Treatment(s) already received-None - Page 13 of 14 Posts on Medivizor
Navigation Menu

Treatment(s) already received-None Posts on Medivizor

Combining Bevacizumab with chemotherapy for advanced colorectal cancer: efficacy evaluation

Combining Bevacizumab with chemotherapy for advanced colorectal cancer: efficacy evaluation

Posted by on Feb 25, 2013 in Colorectal cancer | 0 comments

In a nutshell The present study evaluated whether combining Bevacizumab (Avastin) with chemotherapy for patients with stage IV (metastatic) colorectal cancer (CRC) has any benefits in the terms of survival and quality of life. Main findings: Bevacizumab may be beneficial only as part of certain chemotherapy regimens. Some...

Read More

Treatment options for localized prostate cancer – comparing long-term adverse effects

Treatment options for localized prostate cancer – comparing long-term adverse effects

Posted by on Feb 24, 2013 in Prostate cancer | 0 comments

In a nutshell This study aimed to identify health-related decline in quality of life 4 to 8 years after prostate cancer (PC) treatment. Main finding: measures of quality of life vary based on therapy choice. Some background Treatments for localized PC (confined to the prostate gland) include radical prostatectomy (RP), brachytherapy (BT) and...

Read More

Does Tamoxifen reduce the risk of cancer in a second breast in BRCA1 and BRCA2 carriers?

Does Tamoxifen reduce the risk of cancer in a second breast in BRCA1 and BRCA2 carriers?

Posted by on Feb 24, 2013 in Breast cancer | 0 comments

In a nutshell The risk of breast cancer is high (~80%) in women who inherit a damaged (mutated) gene called BRCA1 or BRCA 2 (‘BRCA carriers’). Following the first diagnosis, their risk of developing another tumor in the second breast within 10 years is 30%. Some background Some types of breast cancer need estrogen (female sex...

Read More

What is the preferred mode of action for patients with Lobular Neoplasia: surgery or observation?

What is the preferred mode of action for patients with Lobular Neoplasia: surgery or observation?

Posted by on Feb 24, 2013 in Breast cancer | 0 comments

In a nutshell The present study tested whether Lobular Neoplasia (LN) diagnosed on Core Needle Biopsy (CNB) leads to breast cancer and if a selected group of patients can be safely observed rather than treated early. The main findings were that not all patients with LN diagnosed on CNB need surgery (excision). Some background Breasts are...

Read More

Radiation therapy for prostate cancer: how long do urinary-related side effects last?

Radiation therapy for prostate cancer: how long do urinary-related side effects last?

Posted by on Feb 24, 2013 in Prostate cancer | 0 comments

In a nutshell The present study examined the duration of urinary-related side effects resulting from radiation therapy. Mild to severe urinary side effects were found to last up to 10 years post radiation therapy. Some background Prostate cancer is a slow growing form of cancer that is often managed by active surveillance or observation (delayed...

Read More

Evaluating the benefits of postoperative chemotherapy for patients with stage II colorectal cancer

Evaluating the benefits of postoperative chemotherapy for patients with stage II colorectal cancer

Posted by on Feb 24, 2013 in Colorectal cancer | 0 comments

In a nutshell This study tested whether chemotherapy after surgery (adjuvant chemotherapy) extends survival and reduces the risk of cancer recurrence in patients with stage II colorectal cancer (CRC). Some background Stage II colorectal cancer (cancer in the colon or rectum) is confined to the digestive tract. It is usually treated with surgery...

Read More

Evaluating survival rates in patients with prostate cancer treated with low-dose-rate brachytherapy

Evaluating survival rates in patients with prostate cancer treated with low-dose-rate brachytherapy

Posted by on Feb 24, 2013 in Prostate cancer | 0 comments

In a nutshell The present study evaluated survival rates in patients with prostate cancer (PC) treated with Low-dose-rate prostate brachytherapy (LDR-PB). The main findings were that LDR-PB alone or combined with hormone therapy offers excellent survival in PC patients. Some background Prostate cancer is the most common type of cancer in men....

Read More